GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Earnings per Share (Diluted)

Fortress Biotech (FRA:CNB1) Earnings per Share (Diluted) : €-4.20 (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech Earnings per Share (Diluted)?

Fortress Biotech's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-4.20.

Fortress Biotech's EPS (Basic) for the three months ended in Mar. 2024 was €0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €-4.20.

Fortress Biotech's EPS without NRI for the three months ended in Mar. 2024 was €0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €-3.77.

During the past 3 years, the average EPS without NRIGrowth Rate was 6.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 19.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 2.90% per year.

During the past 13 years, Fortress Biotech's highest 3-Year average EPS without NRI Growth Rate was 52.10% per year. The lowest was -58.30% per year. And the median was 6.40% per year.


Fortress Biotech Earnings per Share (Diluted) Historical Data

The historical data trend for Fortress Biotech's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Earnings per Share (Diluted) Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.86 -8.01 -10.49 -13.74 -

Fortress Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.94 -3.32 -0.88 - -

Competitive Comparison of Fortress Biotech's Earnings per Share (Diluted)

For the Biotechnology subindustry, Fortress Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's PE Ratio falls into.



Fortress Biotech Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Fortress Biotech's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-55.604-7.365)/7.36628
=-8.55

Fortress Biotech's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-14.184--1.84)/8.93759
=-1.38

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Fortress Biotech  (FRA:CNB1) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Fortress Biotech Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (FRA:CNB1) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines